Pro-203

Preclinical

PProlium Bioscience, Inc

Pro-203 is one of 3 therapeutic programs targeting Systemic Sclerosis (SSc). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Systemic Sclerosis (ssc)Recruiting

Systemic Sclerosis (ssc)Preclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Systemic Sclerosis (ssc)

#DrugCompanyPhaseTrials

Cellcept

Roche

Phase 2

1 2

Tibulizumab

ZZura Bio Inc

Phase 2

1 3

Pro-203

PProlium Bioscience, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Systemic Sclerosis (ssc)

NCT07641634

Clinical

Trials by Indication[1]

Systemic Sclerosis (SSc)1 trial

A Two-part, Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study of PRO-203 in Healthy Adult Volunteers Followed by an Open-label, Single-ascending-dose With Priming Study of PRO-203 in Participants With Systemic Sclerosis

Recruiting·PProlium Bioscience, Inc·Preclinical·NCT07641634·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pro-203. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pro-203. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Prolium Bioscience, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: PProlium Bioscience, Inc

Pro-203

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Systemic Sclerosis (SSc)1 trial

References

Drug Info

Quick Facts

Related News